Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools

References

• Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 2002;28:723-74
   PubMed Web of Science ®Google Scholar
• Vargas-Leguás H, Selva-O’Callaghan A, Campins-Martí M, et al. [Polymyositis-dermatomyositis: incidence in Spain (1997-2004). See comment in PubMed Commons below Med Clin Barc 2007;129:721-4
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis: parts 1 and 2. N Engl J Med 1975;292:344-7; 403-407
   PubMed Web of Science ®Google Scholar
• Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82
   PubMed Web of Science ®Google Scholar
• Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-74
   PubMed Web of Science ®Google Scholar
• Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-35
   PubMedGoogle Scholar
• Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49
   PubMed Web of Science ®Google Scholar
• Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-45
   PubMedGoogle Scholar
• Pilkington C, Tjärnlund A, Bottai M, et al. Progress Report on Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheum 2014;66:S70-1
   Web of Science ®Google Scholar
• Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420-8
   PubMed Web of Science ®Google Scholar
• Hengstman GJD, ter Laak HJ, Vree Egberts WTM, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635-8
   PubMed Web of Science ®Google Scholar
• Wang L, Liu L, Hao H, et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 2014;24:335-41
   PubMed Web of Science ®Google Scholar
• Basnayake SK, Blumbergs P, Tan JA, et al. Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort. Clin Rheumatol 2015;34:603-8
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006;55:791-8
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24
   PubMed Web of Science ®Google Scholar
• Linklater H, Pipitone N, Rose MR, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013;31:767-9
   PubMed Web of Science ®Google Scholar
• Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010;49:1726-33
   PubMed Web of Science ®Google Scholar
• Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-21
   PubMed Web of Science ®Google Scholar
• Hilton-Jones D. Myositis mimics: how to recognize them. Curr Opin Rheum 2014;26:663-70
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Labrador-Horrillo M, Gallardo E, et al. Muscle inflammation, autoimmune Addison’s disease and sarcoidosis in a patient with dysferlin deficiency. Neuromuscul Disord 2006;16:208-9
   PubMed Web of Science ®Google Scholar
• Ng KP, Smith CR, Isenberg DA. Muscular dystrophy mimicking refractory idiopathic inflammatory myositis: a trio of cases. Rheumatology (Oxford) 2007;46:1618-19
   PubMed Web of Science ®Google Scholar
• Milisenda JC, Selva-O’Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun 2014;48-49:118-21
   PubMed Web of Science ®Google Scholar
• Vilela VS, Prieto-González S, Milisenda JC, et al. Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatol Int 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Suzuki S, Satoh T, Sato S, et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 2008;47:1539-42
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013;25:772-7
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martínez MA, Selva-O’Callaghan A, et al. Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun Rev 2014;13:1008-12
   PubMed Web of Science ®Google Scholar
• Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012;64:523-32
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martínez MA, Selva-O’Callaghan A, et al. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 2012;71:993-6
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014;2014:290797
   PubMed Web of Science ®Google Scholar
• Teruya A, Kawamura K, Ichikado K, et al. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 2013;144:1934-6
   PubMed Web of Science ®Google Scholar
• Miller FW. Idiopathic inflammatory myopathies. Rheum Dis Clin N Am 2002;28:xi-xiii
   Google Scholar
• Miró O, Laguno M, Alonso JR, et al. [Clinical course of idiopathic inflammatory myopathies: complications, survival and prognostic factors]. Med Clin (Barc) 1999;112:521-6
   PubMed Web of Science ®Google Scholar
• Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65:1456-61
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Monach PA, Docken WP, Coblyn JS. Characterization of relapses in adult idiopathic inflammatory myopathies. Clin Rheumatol 2006;25:476-81; 43
   PubMed Web of Science ®Google Scholar
• Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL. Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 1998;21:1668-72
   PubMed Web of Science ®Google Scholar
• Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol 1994;21:643-8
   PubMed Web of Science ®Google Scholar
• Sarkar K, Weinberg CR, Oddis CV, et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum 2005;52:2433-8
   PubMedGoogle Scholar
• International Myositis Assessment and Clinical Studies (IMACS) Group website. Available from: www.niehs.nih.gov/research/resources/imacs/diseaseactivity/index.cfm [Last accessed 9 March 2015]
   Google Scholar
• Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010;22:627-32
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Sanchez-Sitjes L, Muñoz-Gall X, et al. Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. Rheumatology (Oxford) 2000;39:914-16
   PubMed Web of Science ®Google Scholar
• Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007;82:441-7
   PubMed Web of Science ®Google Scholar
• Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 2014. [Epub ahead of print]
   Google Scholar
• Ungprasert P, Sanguankeo A. Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Rheumatol Int 2014;34:1455-8
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Fernández-Luque A, Martínez-Gómez X, et al. Venous thromboembolism in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 2011;29:846-9
   PubMed Web of Science ®Google Scholar
• Mercer LK, Moore TL, Chinoy H, et al. Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 2010;49:1699-705
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Fonollosa-Pla V, Trallero-Araguás E, et al. Nailfold capillary microscopy in adults with inflammatory myopathy. Semin Arthritis Rheum 2010;39:398-404
   PubMed Web of Science ®Google Scholar
• Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-7
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen L, Hall JC, Mammen AL, et al. Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clin Exp Rheumatol 2012;30:548-53
   PubMed Web of Science ®Google Scholar
• Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009;80:904-8
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Selva-O’ Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014;13:379-82
   PubMed Web of Science ®Google Scholar
• van Dooren SHJ, van Venrooij WJ, Pruijn GJM. Myositis-specific autoantibodies: detection and clinical associations. Autoimmun Higlights 2011;2:5-20
   PubMedGoogle Scholar
• Marie I, Hatron PY, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013;15:R149
   PubMed Web of Science ®Google Scholar
• Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012;91:206-11
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Oddis CV, Goudeau D, et al. Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford) 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013;23:496-502
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012;51:800-4
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010;49:1713-19
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012;64:513-22
   PubMed Web of Science ®Google Scholar
• Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 2014;150:724-9
   PubMed Web of Science ®Google Scholar
• Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71:710-13
   PubMed Web of Science ®Google Scholar
• Costa AF, Di Primio GA, Schweitzer ME. Magnetic resonance imaging of muscle disease: a pattern-based approach. Muscle Nerve 2012;46:465-81
   PubMed Web of Science ®Google Scholar
• Connor A, Stebbings S, Anne Hung N, et al. STIR MRI to direct muscle biopsy in suspected idiopathic inflammatory myopathy. J Clin Rheumatol 2007;13:341-5
   PubMed Web of Science ®Google Scholar
• Pinal Fernández I, Pallisa Núñez E, Selva-O’Callaghan A, et al. Correlation of ultrasound B-lines with high-resolution computed tomography in antisynthetase syndrome. Clin Exp Rheumatol 2014;32:404-7
   PubMed Web of Science ®Google Scholar
• Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study. J Rheumatol 2015;42:282-91
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Grau JM, Gámez-Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010;123:558-62
   PubMed Web of Science ®Google Scholar
• Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008;59:677-85
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005;14:534-42
   PubMed Web of Science ®Google Scholar
• Debray M, Borie R, Revel M, et al. Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings. Eur J Radiol 2015;84:516-23
   PubMed Web of Science ®Google Scholar
• Stanciu R, Guiguet M, Musset L, et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 2012;39:1835-9
   PubMed Web of Science ®Google Scholar
• Ihn H, Asano Y, Kubo M, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford) 2002;41:1268-72
   PubMed Web of Science ®Google Scholar
• Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 2012;271:589-97
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Selva-O’Callaghan A, Fernadez-Codina A, et al. Pregnancy in adult-onset idiopathic inflammatory myopathy: Report from a cohort of myositis patients from a single center. Semin Arthritis Rheum 2014;44:234-40
   PubMed Web of Science ®Google Scholar
• Nagy-Vincze M, Vencovsky J, Lundberg IE, Dankó K. Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study. J Rheumatol 2014;41:2492-4
   PubMed Web of Science ®Google Scholar
• Rider LG, Dankó K, Miller FW. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol 2014;26:724-41
   PubMed Web of Science ®Google Scholar
• Miller FW, Cooper RG, Vencovský J, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013;65:3239-47
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol 2014;26:704-11
   PubMed Web of Science ®Google Scholar
• Ameye H, Ruttens D, Benveniste O, et al. Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc 2014;46:3147-53
   PubMed Web of Science ®Google Scholar
• Christopher-Stine L. Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2010;22:623-6
   PubMed Web of Science ®Google Scholar